Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Formoterol vs short‐acting beta2‐agonist Withdrawals (any reason) · Patients with asthma Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma (2010) · Cochrane | OR 1.12 [1.02, 1.24] | 7 studies · 22541 participants | Low |
Intervention NR Number of subjects who had one or more exacerbations over the study period in adults ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | OR 0.85 [0.3, 2.43] | 2 studies · 197 participants | Moderate |
Intervention NR Number of subjects who had one or more exacerbations over the study period in children and adolescents ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | OR 0.75 [0.55, 1.01] | 3 studies · 782 participants | Moderate |
Intervention NR Number of exacerbations per 52 weeks in adults ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | no estimate extracted | 2 studies · 197 participants | Moderate |
Intervention NR Number of exacerbations per 52 weeks in children and adolescents ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | no estimate extracted | 1 study · 546 participants | Moderate |
Intervention NR ICS dose at final visit in adults ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | no estimate extracted | 2 studies · 197 participants | Moderate |
Intervention NR ICS dose at final visit in children and adolescents ( · Adults and children with asthma Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and… (2009) · Cochrane | no estimate extracted | 3 studies · 777 participants | Low |
Intervention NR Number of participants with increased cough · patients with prolonged non‐specific cough in children Anti‐histamines for prolonged non‐specific cough in children (2008) · Cochrane | OR 1.47 [0.86, 2.49] | 4 studies · 3090 participants | Moderate |
Regular salmeterol vs placebo All‐cause mortality ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.33 [0.85, 2.08] | 10 studies · 29128 participants | Moderate |
Regular salmeterol vs regular salbutamol All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 0.96 [0.85, 1.1] | 5 studies · 27002 participants | Moderate |
Regular salmeterol vs regular salbutamol All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.37 [0.71, 2.64] | 3 studies · 1181 participants | Moderate |
Regular salmeterol vs regular salbutamol Asthma‐related mortality ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 2.36 [0.78, 7.16] | 4 studies · 26463 participants | Moderate |
Regular salmeterol vs regular salbutamol Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 0.94 [0.37, 2.34] | 3 studies · 1155 participants | Low |
Regular salmeterol vs regular salbutamol Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.04 [0.47, 2.31] | 3 studies · 1186 participants | Low |
Regular salmeterol vs placebo All‐cause mortality ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | no estimate extracted | 4 studies · 1126 participants | Ungraded |
Regular salmeterol vs placebo All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.14 [1.01, 1.28] | 13 studies · 30196 participants | High |
Regular salmeterol vs placebo All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.3 [0.82, 2.05] | 5 studies · 1333 participants | Moderate |
Regular salmeterol vs placebo Asthma‐related mortality ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 3.49 [1.31, 9.31] | 10 studies · 29128 participants | High |
Regular salmeterol vs placebo Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.43 [0.75, 2.71] | 12 studies · 3841 participants | Low |
Regular salmeterol vs placebo Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.72 [1, 2.98] | 5 studies · 1333 participants | Moderate |
Regular salmeterol vs regular salbutamol All‐cause mortality ‐ adults and adolescents · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 1.28 [0.79, 2.05] | 4 studies · 26463 participants | Moderate |
Regular salmeterol vs regular salbutamol All‐cause mortality ‐ children · patients with chronic asthma Regular treatment with salmeterol for chronic asthma: serious adverse events (2008) · Cochrane | OR 0.04 [0, 2.97] | 3 studies · 1152 participants | Low |
Intervention NR Hospital admission/re‐admission · Adults who attend the emergency room for acute asthma Education interventions for adults who attend the emergency room for acute asthma (2007) · Cochrane | RR 0.5 [0.27, 0.91] | 5 studies · 572 participants | High |
Intervention NR Presentation at emergency department · Adults who attend the emergency room for acute asthma Education interventions for adults who attend the emergency room for acute asthma (2007) · Cochrane | RR 0.72 [0.47, 1.11] | 8 studies · 946 participants | Low |
Intervention NR Quality of life (SGRQ) ‐ Total scores SGRQ units. Scale from: 0 to 100. · Adults who attend the emergency room for acute asthma Education interventions for adults who attend the emergency room for acute asthma (2007) · Cochrane | no estimate extracted | 2 studies · 356 participants | Low |